Three‐Dimensional Chromosomal Landscape Revealing miR‐146a Dysfunctional Enhancer in Lupus and Establishing a CRISPR‐Mediated Approach to Inhibit the Interferon Pathway
- 26 December 2023
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 76 (3) , 384-395
Abstract
Objective: The diminished expression of microRNA‐146a (miR‐146a) in systemic lupus erythematosus (SLE) contributes to the aberrant activation of the interferon pathway. Despite its significance, the underlying mechanism driving this reduced expression remains elusive. Considering the integral role of enhancers in steering gene expression, our study seeks to pinpoint the SLE‐affected enhancers responsible for modulating miR‐146a expression. Additionally, we aim to elucidate the mechanisms by which these enhancers influence the contribution of miR‐146a to the activation of the interferon pathway.Methods: Circular chromosome conformation capture sequencing and epigenomic profiles were applied to identify candidate enhancers of miR‐146a. CRISPR activation was performed to screen functional enhancers. Differential analysis of chromatin accessibility was used to identify SLE‐dysregulated enhancers, and the mechanism underlying enhancer dysfunction was investigated by analyzing transcription factor binding. The therapeutic value of a lupus‐related enhancer was further evaluated by targeting it in the peripheral blood mononuclear cells (PBMCs) of patients with SLE through a CRISPR activation approach.Results: We identified shared and cell‐specific enhancers of miR‐146a in distinct immune cells. An enhancer 32.5 kb downstream of miR‐146a possesses less accessibility in SLE, and its chromatin openness was negatively correlated with SLE disease activity. Moreover, CCAAT/enhancer binding protein α, a down‐regulated transcription factor in patients with SLE, binds to the 32.5‐kb enhancer and induces the epigenomic change of this locus. Furthermore, CRISPR‐based activation of this enhancer in SLE PBMCs could inhibit the activity of interferon pathway.Conclusion: Our work defines a promising target for SLE intervention. We adopted integrative approaches to define cell‐specific and functional enhancers of the SLE critical gene and investigated the mechanism underlying its dysregulation mediated by a lupus‐related enhancer. imageKeywords
Funding Information
- National Natural Science Foundation of China (31930037, 32141004)
This publication has 40 references indexed in Scilit:
- Super-Enhancers in the Control of Cell Identity and DiseaseCell, 2013
- An integrated encyclopedia of DNA elements in the human genomeNature, 2012
- Cistrome: an integrative platform for transcriptional regulation studiesGenome Biology, 2011
- A Functional Variant in MicroRNA-146a Promoter Modulates Its Expression and Confers Disease Risk for Systemic Lupus ErythematosusPLOS Genetics, 2011
- PU.1 and C/EBPα synergistically program distinct response to NF-κB activation through establishing monocyte specific enhancersProceedings of the National Academy of Sciences, 2011
- Histone H3K27ac separates active from poised enhancers and predicts developmental stateProceedings of the National Academy of Sciences of the United States of America, 2010
- MicroRNA‐146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteinsArthritis & Rheumatism, 2009
- Histone modifications at human enhancers reflect global cell-type-specific gene expressionNature, 2009
- Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemiaAnnals of the Rheumatic Diseases, 2005
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997